Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company has achieved a significant business development (BD) authorization, granting Pfizer exclusive rights to develop, produce, and commercialize a dual-specific antibody product targeting PD-1 and VEGF in regions outside mainland China [1][2] - The innovative pipeline is actively advancing, with clinical trials validating the efficacy and safety of the PD-1/L1 antibody combined with VEGF antibody in various tumors [3] - The company anticipates substantial revenue growth due to the upcoming approvals of multiple new products, with revised revenue forecasts for 2025-2027 being 40.2 billion, 22.4 billion, and 26.3 billion respectively, reflecting a year-on-year growth of 236.4%, -44.1%, and 17.4% [4][10] Financial Summary - The projected revenue for 2025 is 40.2 billion, with a net profit of 28.5 billion, resulting in an earnings per share (EPS) of 4.63 [4][10] - The company expects a gross margin of 92.8% in 2025, with a return on equity (ROE) of 35.2% [10][11] - The financial outlook includes a significant increase in net profit for 2025, projected at 2,854 million, which is a 305.0% increase year-on-year [10][11]

公司报告 | 公司点评 立昂微（605358） 证券研究报告 营收创新高与盈利困境并存，行业复苏曙光初现 事件：公司发布 2024 年年度报告和 2025 年一季报。2024 年度公司实现营业收入 30.92 亿元，同 比增长 14.97%；实现归母净利润-2.66 亿元，同比下降 504.18%；扣非归母净利润-2.66 亿元，同比 下降 152.04%。2025Q1 公司实现营业收入 8.20 亿元，同比增长 20.82%；实现归母净利润-0.81 亿 元，同比增亏；实现扣非归母净利润-0.81 亿元，同比增亏。 点评：营收再创新高展现增长韧性，盈利承压待解多重挑战。2024 年，公司全员攻坚克难， 推动 产能、技术、市场与良率实现显著提升，发展态势持续向好，营业收入创历史新高，市场份额持续 扩大，2024 年公司营业收入的大幅增加主要系 2024 年半导体行业景气度的见底回暖及公司加强市 场拓展、调整产品结构，产品销量同比实现了大幅增长所致。然而，由于欧美发达经济体受高利率 与能源转型阵痛制约增速放缓，叠加地缘政治冲突及产业链重构加速，使得公司经营迎来多重挑战： 产能扩张带来成本压力，产品降价导致毛利率 ...

Investment Rating - The investment rating for the company is "Buy" [6]. Core Insights - The company has achieved a significant business development (BD) authorization, granting Pfizer exclusive rights to develop, produce, and commercialize a dual-specific antibody product targeting PD-1 and VEGF in regions outside mainland China [1][2]. - The innovative pipeline is actively progressing, with clinical trials validating the efficacy and safety of the PD-1/L1 antibody combined with VEGF antibody in various cancers [3]. - Future revenue growth is anticipated due to the upcoming approvals of multiple new products, leading to a substantial increase in revenue and net profit forecasts for 2025-2027 [4]. Financial Projections - Revenue projections for 2025-2027 are estimated at 40.2 billion, 22.4 billion, and 26.3 billion CNY, reflecting year-on-year growth rates of 236.4%, -44.1%, and 17.4% respectively [4][10]. - The net profit forecasts for the same period are 28.5 billion, 11.2 billion, and 13.9 billion CNY, with year-on-year growth rates of 305.0%, -60.6%, and 23.4% respectively [4][10]. - Earnings per share (EPS) are projected to be 4.63, 1.82, and 2.25 CNY for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings (PE) ratios of 12, 30, and 24 [4][10]. Clinical Development - The licensed product has initiated multiple clinical trials, with a monotherapy for PD-L1 positive non-small cell lung cancer having received approval for Phase III clinical trials [3]. - Combination chemotherapy for non-small cell lung cancer and other indications are currently in Phase II clinical trials [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][8]. Core Views - The company reported a strong performance in non-interest income and maintained prudent asset quality management [1]. - In Q1 2025, the company achieved operating revenue of 2.971 billion yuan, a year-on-year increase of 10.04%, and a net profit attributable to shareholders of 1.084 billion yuan, up 13.81% year-on-year [4][5]. - The total asset scale at the end of Q1 was 389.015 billion yuan, reflecting a year-on-year growth of 6.67%, with a non-performing loan ratio of 0.76%, down 1 basis point quarter-on-quarter [4][5]. - The net interest margin for the quarter was 2.61%, a decrease of 22 basis points year-on-year [4][5]. Summary by Sections Financial Performance - The company’s Q1 investment income and fair value changes amounted to 471 million yuan, a year-on-year increase of 9.06%, outperforming industry levels [5]. - The net commission income reached 71 million yuan, showing a significant year-on-year growth of 495.23% [5]. Asset Quality - The company maintained a stable overall asset quality, with a non-performing loan ratio of 0.76% at the end of Q1, down 1 basis point from the previous quarter [5]. - The company continues to adopt a cautious approach, increasing provisions, with asset impairment losses rising by 13% year-on-year [5]. Future Outlook - The company expects further downward pressure on interest margins due to a new round of interest rate cuts, which will benefit its deposit structure primarily composed of personal deposits [8]. - The updated profit forecast for 2025-2027 anticipates operating revenues of 11.712 billion, 12.225 billion, and 13.570 billion yuan, respectively, with net profits of 4.238 billion, 4.687 billion, and 5.214 billion yuan [8][29].

公司报告 | 季报点评 华致酒行（300755） 证券研究报告 Q1 主动调整业绩短期承压，25 年利润修复弹性可期 事件：公司发布 25 年一季报，2025Q1 公司营业收入/归母净利润/扣非归 母净利润分别为 28.52/0.85/0.75 亿元（同比-31.01%/-34.19%/-41.27%）。 严格落实十八字行动方针，25Q1 调整期业绩阶段承压。25Q1 公司营收端 承压相对明显，预计主要系：①25Q1 酒类流通行业整体仍处于调整期，需 求相对偏弱；②公司自 24Q4 开启包括"去库存、促动销"在内的 18 字行 动方针，主动解决快速发展阶段积累的问题，为后续高质量增长奠基。 计提存货跌价利润承压，经营性现金流表现强于利润。25Q1 公司毛利率 10.44%（同比-0.04pcts）、销售费用率 4.67%（同比+0.01pcts）、管理费用率 1.28%（同比+0.18pcts）、归母净利率 2.99%（同比-0.15pcts）。25Q1 公司毛 利率小幅下滑主要系行业周期性深度调整，主销名酒市场价格呈下降趋势， 此外公司基于谨慎性原则对部分存货计提了存货跌价准备，导致净利润同 比减少。25Q ...

Investment Rating - The report maintains an "Accumulate" rating for the company [6][14]. Core Views - Short-term performance is under pressure due to non-operating factors, but long-term prospects remain positive with steady progress in new unit construction and a proposed share buyback plan by the chairman [2][14]. - The company is expected to achieve a net profit of 10.6 billion yuan in 2025, representing a year-on-year increase of 21% [14]. Financial Summary - Revenue projections for the company are as follows: - 2023: 74.957 billion yuan - 2024: 77.272 billion yuan (YOY +3.1%) - 2025: 86.127 billion yuan (YOY +11.5%) - 2026: 93.330 billion yuan (YOY +8.4%) - 2027: 108.026 billion yuan (YOY +15.7%) [4][14]. - Net profit (attributable to the parent company) is projected as follows: - 2023: 10.624 billion yuan - 2024: 8.777 billion yuan (YOY -17.4%) - 2025: 10.618 billion yuan (YOY +21.0%) - 2026: 10.938 billion yuan (YOY +3.0%) - 2027: 12.371 billion yuan (YOY +13.1%) [4][14]. - Earnings per share (EPS) estimates are: - 2023: 0.52 yuan - 2024: 0.43 yuan - 2025: 0.52 yuan - 2026: 0.53 yuan - 2027: 0.60 yuan [4][14]. Target Price - The target price for the company is set at 11.44 yuan, based on a 22x PE ratio for 2025 [7][14]. Market Data - The current price of the stock is 9.65 yuan, with a market capitalization of 198.481 billion yuan [7][14]. - The stock has a 52-week price range of 8.99 to 12.22 yuan [14]. Investment Highlights - The company is actively pursuing the construction of new nuclear power units, with 19 units currently under construction or planned [14]. - A share buyback plan of 300 to 500 million yuan is proposed, with a buyback price not exceeding 13.98 yuan per share [14]. - The company plans to invest 1 billion yuan in a nuclear fusion company, indicating a forward-looking strategy in the energy sector [14].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][8]. Core Views - The report highlights that the company's non-interest income performance is strong, and asset quality management is prudent [1][5]. - In Q1 2025, the company achieved operating revenue of 2.971 billion yuan, a year-on-year increase of 10.04%, and a net profit attributable to shareholders of 1.084 billion yuan, up 13.81% year-on-year [4][5]. - The total asset scale at the end of Q1 was 389.015 billion yuan, reflecting a year-on-year growth of 6.67%, with a non-performing loan ratio of 0.76%, down 1 basis point quarter-on-quarter [4][5]. Summary by Sections Financial Performance - The company reported a Q1 investment income and fair value changes of 471 million yuan, a year-on-year increase of 9.06%, outperforming industry levels [5]. - The net interest margin for Q1 was 2.61%, a decrease of 22 basis points year-on-year, primarily due to lower loan rates and a decline in the proportion of high-yield personal loans [5][6]. Asset Quality - The non-performing loan ratio at the end of Q1 was 0.76%, with a provision coverage ratio of 489.56%, down 10.95 percentage points quarter-on-quarter [4][5]. - The company continues to adopt a cautious approach, increasing provisions, with asset impairment losses rising by 13% year-on-year [5]. Future Outlook - The report projects operating revenues for 2025-2027 to be 11.712 billion, 12.225 billion, and 13.570 billion yuan, respectively, with net profits of 4.238 billion, 4.687 billion, and 5.214 billion yuan [6][8]. - The company maintains a strong capital position, with a projected PB ratio of 0.82, 0.73, and 0.66 for the years 2025, 2026, and 2027, respectively [6][8].

证券研究报告 | 公司点评 | 汽车零部件 雷迪克(300652) 报告日期：2025 年 05 月 28 日 2025Q1 归母净利润同增 6%，丝杠领域拓展打开成长空间 ——雷迪克点评报告 盈利能力：2024 年销售毛利率、净利率分别约 31.61%、16.24%，同比下降 0.41、2.23pct。主要系新能源汽车前装市场营收占比提升所致。其中，轮毂单元 毛利率 27.45%，同比下降 2.69pct；圆锥轴承毛利率 30.63%，同比增长 1.04pct； 分离轴承 42.15%，同比增长 3.28pct；轮毂轴承 34.82%，同比增长 1.23pct。 2025Q1 单季度销售毛利率 30.82%，同比下降 4.67pct；销售净利率 18.76%，同比 下降 3.06pct。 费用端：2024 年期间费用率 13.03%，同比增长 0.92pct。其中，销售、管理、研 发、财务费用率分别同比-0.08、+0.53、+0.29、+0.19pct。2025Q1 期间费用率 9.76%，同比下降 1.45pct。 ❑ 拟收购誊展精密布局丝杠领域，发挥协同效应实现产业链延伸 2025 年 3 月 7 日 ...

股权激励锚定稳健增长，基本面强劲延续 爱玛科技(603529) —爱玛科技公司公告点评 耐用消费品[Table_Industry] /可选消费品 [Table_Invest] 评级： 增持 | [table_Authors] 刘佳昆(分析师) | 毛宇翔(分析师) | [Table_Target] 目标价格： | 55.47 | | --- | --- | --- | --- | | 021-38676666 | 021-38676666 | | | | 登记编号 S0880524040004 | S0880524080013 | | | 本报告导读： 公司发布员工持股计划，激励彰显长期发展信心，强化业务团队凝聚力。 投资要点： 请务必阅读正文之后的免责条款部分 | [Table_Finance] 财务摘要（百万元） | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 21,036 | 21,606 | 28,112 | 33,197 | 38,276 | | (+/-)% | 1.1 ...

Investment Rating - The report does not explicitly state the investment rating for Chow Tai Seng, but it emphasizes a focus on transformation and stabilization for the main brand by 2025, indicating a positive outlook for the company's strategic direction [2][3]. Core Insights - Chow Tai Seng is focusing on a four major brands matrix to build a complete system that covers different consumption levels through product upgrades and brand differentiation [2][9]. - The main brand is undergoing a transformation towards a retail-oriented business model, with a priority on the One-Pool Inventory strategy to enhance product structure and profitability [2][3]. - The company aims to create a core model store with annual sales exceeding 100 million RMB through high-end positioning and product quality improvements under the Chow Tai Seng x National Treasure brand [4][11]. - The organizational structure is being optimized to strengthen talent reserves and incentive mechanisms to support the company's transformation [12]. Summary by Sections Brand Strategy - Chow Tai Seng is focusing on four major brands: Chow Tai Seng Consolidated (main brand), Chow Tai Seng x National Treasure, Chow Tai Seng Classic, and Turning Pearl Pavilion, each targeting different consumer segments and emphasizing product differentiation [2][9]. - The main brand is set to enhance its product offerings and shift towards a retail model, while the National Treasure brand aims for high-end positioning with unique product craftsmanship [4][11]. Inventory and Marketing - The One-Pool Inventory strategy is being deepened, with graded management of franchisees and a focus on creating explosive products through enhanced marketing efforts [3][10]. - The company is investing in both online and offline marketing to strengthen brand awareness and drive sales [10]. Organizational Development - The company is optimizing its organizational structure to clarify corporate values and strategic systems, aiming for a win-win situation for all stakeholders [12]. - A focus on leadership development and talent management is being emphasized to support the company's strategic goals [12].